CSV April 23, 2023 through April 24, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE	ADDITIONAL R	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR INJECTION	EQUIREMENTS/*USP Reference Standards <11>*							Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.13 to: (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octah

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.90
ASCORBIC ACID INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Chromatographic system*/*Column*: Change 150-cm × 6-mm; packing L39 to: 15-cm × 6-mm; packing L39
RIFABUTIN	CHEMICAL INFORMATION	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change 847.00 to: 847.02 AND Change (9*S*,12*E*,14*S*,15*R*,16*S*,17*R*,18*R*,19*R*,20*S*,21*S*,22*E*,24*Z*)-6,16,18,20-Tet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rahydroxy-1?-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2*H*-furo[2?,3?:7,8]naphth[1,2-*d*]imidazole-2,4?-piperidine]-5,10,26-(3*H*,9*H*)-trione-16-acetate to: (9*S*,12*E*,14*S*,15*R*,16*S*,17*R*,18*R*,19*R*,20*S*,21*S*,22*E*,24*Z*)-6,18,20-Trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienimino)-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2*H*-furo[2',3':7,8]naphtho[1,2-*d*]imidazole-2,4'-piperidin]-16-yl acetate
DOXYCYCLINE HYCLATE	CHEMICAL INFORMATION	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change 1025.87 to: 1025.88
FLUOCINOLONE ACETONIDE	*Organic Impurities*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Acceptance criteria*/*Total impurities*: Change NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the *Standard solution*. to: NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetonide from the *Sample solution*.
NANDROLONE DECANOATE	ASSAY/ *Procedure*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of Nandrolone Decanoate ($C_{28}H_{44}O_3$) in the portion of Nandrolone Decanoate taken: to: Calculate the percentage of nandrolone decanoate ($C_{28}H_{44}O_3$) in the portion of Nandrolone Decanoate taken:
IBUPROFEN ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*: Change Result = $(R_U/R_S) \times C_S \times V \times (D/W_U) \times (1/L) \times 100$ *R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$= peak area ratio of ibuprofen to benzophenone from the *Sample solution* R_S = peak area ratio of ibuprofen to benzophenone from the *Standard solution* C_S = concentration of USP Ibuprofen RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL D = density of Oral Suspension (g/mL) W_U = weight of the portion of Oral Suspension

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								added to the *Medium* (g) *L* = label claim (mg/mL) to: Result = $(R_U/R_S) \times C_S \times V \times (d/W_U) \times D \times (1/L) \times 100$ R_U = peak area ratio of ibuprofen to benzophenone from the *Sample solution* R_S = peak area ratio of ibuprofen to benzophenone from the *Standard solution* C_S = concentration of USP Ibuprofen RS in the *Standard solution* (mg/mL) *V* = volume of *Medium*, 900

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL *d* = density of Oral Suspension (g/mL) W_U = weight of the portion of Oral Suspension added to the *Medium* (g) *D* = dilution factor of the *Sample solution*, 2 *L* = label claim (mg/mL)
APREPITANT CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change **Test 1** Dilute 1 mL of phosphoric acid with water to 1 L. to: **Test 1** AND Change **Dilute phosphoric acid:**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: **Dilute phosphoric acid:** Dilute 1 mL of phosphoric acid with water to 1 L.
DOXYCYCLINE HYCLATE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Table 2*, footnote b: Change (4*S*,4a*R*,5*S*,5a*R*,6*R*,12a*S*)-2-Acetyl-4-(dimethylamino)-4a,5a,6,12a-tetrahydro-3,5,10,12,12a-pentahydroxy-6-methyl-tetracene-1,11-dioxo-2-naphthacenecarboxamide. to: (4*S*,4a*R*,5*S*,5a*R*,6*R*,12a*S*)-2-Acetyl-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-m

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethyl-4a,5a,6,12a-tetrahydrotetrac ene-1,11(4*H*,5*H*)-dione.
DIMENHYDRINATE TABLETS	OTHER COMPONENTS/ *8-Chlorotheophylline*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*: Change C_U = nominal concentration of dimenhydrinate in the *Sample solution* (mg/mL) to: C_U = determined concentration of dimenhydrinate in the *Sample solution*, as obtained in the *Assay* (mg/mL)
AZITHROMYCIN FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In USP Azithromycin Related Compound F RS: Change 762.97 to: 762.98

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATRACURIUM BESYLATE	CHEMICAL INFORMATION	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	AND In USP Desosaminylazithromycin RS: Change 590.79 to: 590.80 Change 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimeth oxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester to: 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
CARBAMAZEPINE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In USP Carbamazepine Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 238.28 to: 238.29 AND In USP Carbamazepine Related Compound B RS: Change 193.24 to: 193.25 AND In USP 9-Methylacridine RS: Change 193.24 to: 193.25
BOTANICAL EXTRACTS	PREPARATIONS	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *General Pharmacopeial Requirements/Pesticide Residues*: Change where *L* is the limit in the original article

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								as listed in *Table 4* (see *Pesticide Residue Analysis* under *Articles of Botanical Origin <561>*) to: where *L* is the limit in the original article as listed in *Table 5* (see *Pesticide Residue Analysis* under *Articles of Botanical Origin <561>*)
DOXYCYCLINE HYCLATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change 480.13

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MUPIROCIN NASAL OINTMENT	*Related compounds/Table 1*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	to: 480.90 In footnote 2: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
ACYCLOVIR	ASSAY/ *Procedure*	*USPNF Online*	Online	29-Apr-2022	1-May-2023	*NA*	*NA*	In the *Sample solution*: Change 0.1 N sodium hydroxide to: 0.01 N sodium hydroxide
DACARBAZINE FOR INJECTION	IMPURITIES	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Delete *Limit of 2-Azahypoxanthine* test
MUPIROCIN OINTMENT	IM PUR ITIES/*Organic Impurities*/*Table 2*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote b: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S* ,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H* -furo[3, 2-*c*]pyran-6-yl]-3-methylbut-2-enoyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
MECAMYLAMINE HYDROCHLORIDE	*USP Reference standards* <11>	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In USP Mecamylamine Related Compound A RS: Change *N*,1,7,7-Tetramethyl bicyclo [2.2.1]heptan-2-amine. $C_{11}H_{21}N$ 167.29 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N ,1,7,7-Tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride. $C_{11}H_{21}N \cdot HCl$ 203.75
MUPIROCIN CALCIUM	CHEMICAL INFORMATION	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Change 1075.34 to: 1075.35
CHROMATOGRAPHY	ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS	*USPNF Online*	Online	29-Apr-2022	1-Dec-2022	*NA*	*NA*	In *Liquid Chromatography: Isocratic Elution/Injection volume*: Change Result = (V_{inj2} = V_{inj1} (L_2 d_{c2}^2)/(L_1 d_{c1}^2) to: $V_{inj2} = V_{inj1}$ (L_2 d_{c2}^2)/(L_1 d_{c1}^2) AND In *Liquid Chromatography: Gradient Elution/Column parameters and flow rate*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MUPIROCIN CREAM	*Related compounds/Table 1*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Change $F_2 = F_2 \times [(dc_2^2 \times dp_1)/(dc_1^2 \times dp_2)]$ to: $F_2 = F_1 \times [(dc_2^2 \times dp_1)/(dc_1^2 \times dp_2)]$ In footnote 2: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
BROMOCRIPTINE MESYLATE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In *Analysis*: Change bromocriptine mesylate ($C_{32}H_{40}BrN_5O_5 \cdot CH_4SO_3$) to: bromocriptine ($C_{32}H_{40}BrN_5O_5$) AND In *Tolerances*: Change bromocriptine mesylate ($C_{32}H_{40}BrN_5O_5 \cdot CH_4SO_3$) to: bromocriptine ($C_{32}H_{40}BrN_5O_5$)
DACARBAZINE	IDENTIFICATIO	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR INJECTION	N							Identification test *C*
MUPIROCIN CALCIUM	IM PURITIES/*Organic Impurities*/*Table 1*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote b: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
ONDANSETRON ORAL SOLUTION	*USP Reference standards <11>*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H* -carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4*H* -carbazol-4-one. USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9-tet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rahydr o-4*H* -carbazol-4-one . USP Ondansetron Related Compound D RS 9-Methyl-3-met hylene-1,2,3,9-t etra hydro-4*H* -carbazol-4-one .
ACYCLOVIR FOR INJECTION	IM PUR ITIES/ *Procedure*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Standard solution A*: Change 0.5 ?g/mL of *Acyclovir standard solution* in *Solution A* to: 0.5 ?g/mL of USP Acyclovir RS from *Acyclovir standard solution* in *Solution A*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Standard solution B*: Change 5 ?g/mL of *Guanine solution* in *Solution A* to: 5 ?g/mL of guanine from *Guanine solution* in *Solution A* AND In *Analysis 1*: Change r_S = peak response of guanine in the *Standard solution* C_S = concentration of guanine in the *Standard solution* to: r_S = peak response of guanine in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution B C_S = concentration of guanine in *Standard solution B* AND In *Analysis 2*: Change r_S = peak response of acyclovir in the *Standard solution* C_S = concentration of USP Acyclovir RS in the *Standard solution* (mg/mL) to: r_S = peak response of acyclovir in *Standard solution A* C_S = concentration of USP Acyclovir

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS in *Standard solution A* (mg/mL)
CHROMATOGRAPHY	SYSTEM SUITABILITY	*USPNF Online*	Online	25-Mar-2022	1-Dec-2022	*NA*	*NA*	Change **System Repeatability—Assay of an Active Substance or an Excipient** to: **System Repeatability**
DIBASIC POTASSIUM PHOSPHATE	ASSAY/ *Procedure*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Analysis*: Change Titrate the *Blank* with 1 N sodium hydroxide VS, and record the volume of 1 N sodium hydroxide VS consumed. Titrate the excess acid in the *Sample solution* with 1 N sodium hydroxide VS to the inflection point at pH 4,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and record the buret reading. to: Titrate the *Blank* potentiom etrically with 1 N sodium hydroxide VS, and record the volume of 1 N sodium hydroxide VS consumed. Titrate the excess acid in the *Sample solution* potenti ometrically with 1 N sodium hydroxide VS to the inflection point at pH 4, and record the buret reading.
ONDANSETRON TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Table 1*/footnotes: Change [b] 1,2,3,9-Tetrahyd ro-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								9-methyl-4*H*-carbazol-4-one.[c]
								1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one.[d]
								3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one.[e]
								1,2,3,9-Tetrahydro-9-methyl-3-[1*H*-imidazol-1-yl)methyl]-4*H*-carbazol-4-one. to:[b]
								9-Methyl-1,2,3,9

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-tet rahydr o-4*H* -carbazol-4-one .[c] 9-Methyl-3-met hylene-1,2,3,9-t etra hydro-4*H* -carbazol-4-one .[d] 3-[(Dimethylami no)methyl]-9-m ethyl-1,2,3,9-tet rahydr o-4*H* -carbazol-4-one .[e] 3-[(1*H* -Imidazol-1-yl)m ethyl]-9-methyl- 1,2,3,9-tetrahyd ro-4*H* -carbazol-4-one .
POWDERED VALERIAN EXTRACT	DEFINITION	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change calculated as the sum of hydr oxyvalerenic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid, acetoxyvalerenic acid, and valerenic acid, on the dried basis. to: calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid, on the anhydrous basis.
PANTOPRAZOLE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In USP Pantoprazole Related Compound E RS: Change A mixture of the stereoisomers of 6,6?-bis(difluoromethoxy)-2,2?-bis[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1*H*,1?*H*-5,5?-bibenzimidazolyl. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								6,6?-Bis(difluoromethoxy)-2,2?-bis[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1*H*,1?*H*-5,5?-bibenzimidazole.
CORN STARCH	IM PURITIES/*Limit of Sulfur Dioxide*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Bromophenol blue indicator solution*: Change 0.2 mg/mL of bromophenol blue in dilute alcohol. Filter if necessary. to: Dissolve 100 mg of bromophenol blue in 100 mL of dilute alcohol (1 in 5), and filter if necessary.
ONDANSETRON TABLETS	ADDITIONAL REQUIREMENT	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S/*USP Reference Standards <11>*							Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride.
POWDERED VALERIAN EXTRACT	COMPOSITION /*Content of Valerenic Acids*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Acceptance criteria*: Change calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								valerenic acid on the dried basis to: calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid on the anhydrous basis
MAGNESIUM OXIDE	IM PURITIES/*Limit of Calcium*	*USPNF Online*	Online	25-Feb-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of Magnesium Hydroxide in the *Sample solution* (mg/mL) to: C_U = concentration of Magnesium Oxide in the *Sample solution* (mg/mL)
IODIXANOL	IM PURITIES/*Limit of 2-Methoxyeth*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Standard stock solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	anol							0.005 mg/mL of methanol and 0.01 mg each of isopropyl alcohol, secondary butyl alcohol, and 2-methoxyethanol in *Internal standard solution* to: 0.005 mg/mL of methanol and 0.01 mg/mL each of isopropyl alcohol, secondary butyl alcohol, and 2-methoxyethanol in *Internal standard solution*
PROPYLENE GLYCOL DIACETATE	IM PURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change r_S = sum of all the peak areas, excluding the solvent peaks from the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution to: r_S = sum of all the peak areas, excluding the solvent peaks from the *Sample solution*
ZOLEDRONIC ACID	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change r_U = peak response of zoledronic acid from the *Sample solution* to: r_U = peak response of any individual impurity from the *Sample solution*
ECONAZOLE NITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In USP Econazole Related Compound B RS: Change Econazole amine; 2-[(4-Chloroben

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								zyl)oxy]-2-(2,4-dichlorophenyl)ethanamine. $C_{15}H_{14}Cl_3NO$ 330.64 to: Econazole amine; 2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethanamine nitrate. $C_{15}H_{14}Cl_3NO \cdot HNO_3$ 393.65
TRAZODONE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In footnote f of *Table 2*: Change 1,1-Bis{2-chloro-[4-(3-{1,2,4-triazolo[4,3-*a*]pyridin-3-(2*H*)-on-2-yl}propyl)piperazine-1-yl]phenyl}ethane trihydrochloride. to: 2,2'-{[Ethane-1,1-diylbis(3-chlor

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-4,1-phenylene)bis(piperazine-4,1-diyl)]bis(propane-3,1-diyl)}bis([1,2,4]triazolo[4,3-*a*]pyridin-3(2*H*)-one).
BEHENOYL POLYOXYLGLYCERIDES	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change If the volume of 0.5 N sodium hydroxide VS required for the titration is less than 2 mL, to: If the volume of 0.5 N alcoholic potassium hydroxide VS required for the titration is less than 2 mL,
ONDANSETRON ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. $C_{16}H_{20}N_2O$ · HCl 292.80 to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. $C_{16}H_{20}N_2O$ · HCl 292.81 AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one . to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								9-Methyl-3-methylene-1,2,3,9-tetra hydro-4*H*-carbazol-4-one.
LEVOFLOXACIN	IMPURITIES/*Organic Impurities, Procedure 1*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	Change **Solution A**, **Mobile phase**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*.
FULVESTRANT	*Related compounds*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In footnote 1 of table: Change Estra-1,3,5(10)-triene-6-one-3,17-diol,7-[9-[(4,4,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-6-one-3,17?-diol AND In footnote 2: Change Estra-1,3,5(10),6-tetraene-3,17-diol,7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10),6-tetraene-3,17?-diol AND In footnote 3: Change Estra-1,3,5(10)-triene-3,17-diol,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfonyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol AND In footnote 4: Change Estra-1,3,5(10)-triene-3,17-diol, 7-{9-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonylsulfinyl]nonyl}-(7?,17?) to: 7?-{9-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonylsulfinyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol AND In footnote 5:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change 7,7-Nonamethylene-bis(estra-1,3,5(10)-triene-3,17-diol-(7?,17?) to: 7?,7?-Nonamethylenebis[estra-1,3,5(10)-triene-3,17?-diol] AND In footnote 6: Change Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol
ONDANSETRON HYDROCHLORIDE	*USP Reference standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 9-Methyl-1,2,3,9-tet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rahydr o-4*H* -carbazol-4-one . AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahy dro-9-methyl-3-met hylene-4*H* -carbazol-4-one . to: 9-Methyl-3-met hylene-1,2,3,9-t etra hydro-4*H* -carbazol-4-one .
WARFARIN SODIUM FOR INJECTION	ADDITIONAL R EQUIREMENT S/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Warfarin Related Compound A RS: Change 3-(*o* -Hydroxyphenyl)-5-phenyl-2-cyc

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lohexen-1-one. to: 3-(2-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. AND Change 264.33 to: 264.32
SORAFENIB TABLETS	PERFORMANCE TESTS/ *Dissolution* <*711*>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Tolerances*: Change NLT 75 (*Q*) of the labeled amount of sorafenib ($C_{21}H_{16}ClF_3N_4O_3$) is dissolved. to: NLT 75% (*Q*) of the labeled amount of sorafenib ($C_{21}H_{16}ClF_3N_4O_3$) is dissolved.
ORPHENADRINE CITRATE INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Orphenadrine Related Compound B RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N-Ethyl-*N*,*N* -dimethyl [2-2(methylbenzhydryloxy)ethyl]ammonium chloride; also known as *N*-ethyl-*N*,*N* -dimethyl-2-[phenyl(*o* -tolyl)methoxy]ethanaminium chloride. to: *N*-Ethyl-*N*,*N* -dimethyl [2-(2-methylbenzhydryloxy)ethyl]ammonium chloride; also known as *N*-Ethyl-*N*,*N* -dimethyl-2-[phenyl(2-tolyl)methoxy]ethanaminium chloride.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 3

- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- …
- Next page Next ›
- Last page Last »